30 results
8-K
EX-99.2
ORTX
Orchard Therapeutics plc
10 Jan 22
Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones
7:05am
Neurodegenerative disorders Approach leverages success of Libmeldy in whole-brain secretion of ARSA from fully distributed microglial cells Targets include GRN-FTD … for autoimmune diseases mAb vectorization technology to target specific tumors or other targets
23 Libmeldy: Reach reimbursement agreement with at least two
8-K
EX-99.1
ORTX
Orchard Therapeutics plc
12 Nov 20
NOD2 mutation revealed as Crohn’s disease (CD) genetic target, associated with 7-10% of all CD cases in the U.S. and Europe
4:18pm
on restoring gene function in patients with specific genetic susceptibility, this approach targets neuroinflammatory responses to support neuronal … for NOD2-CD
Orchard’s preclinical program in CD targets mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2) gene
6-K
EX-99.1
ORTX
Orchard Therapeutics plc
5 Nov 18
Orchard Therapeutics Announces Pricing of Initial Public Offering
7:40am
portfolio of autologous ex vivo gene therapies targets serious and life-threatening rare diseases, initially primary immune deficiencies
6-K
EX-99.2
ORTX
Orchard Therapeutics plc
5 Nov 18
Orchard Therapeutics Announces Pricing of Initial Public Offering
7:40am
ex vivo gene therapies targets serious and life-threatening rare diseases, initially primary immune deficiencies, neurometabolic disorders
8-K
EX-99.1
mljodaoh74q91fn6zmuw
7 May 20
Orchard Therapeutics Unveils New Strategic Plan and Reports First Quarter 2020 Financial Results
7:03am
DEF 14A
9tpkg7a 52
29 Apr 20
Definitive proxy
4:02pm
PRE 14A
0xcrobta
14 Apr 20
Preliminary proxy
4:46pm
DEFA14C
u2k gr85qq77nc
5 Oct 23
Additional information
4:43pm
DEFA14A
pb0hgupt
17 Oct 23
Additional proxy soliciting materials
4:32pm
DEFM14A
kn0e4u8k oq8
16 Nov 23
Proxy related to merger
4:45pm
PREM14A
6z7 bt1uv
3 Nov 23
Preliminary proxy related to merger
5:11pm
POSASR
sqmmw69033tggnl
28 Feb 20
Automatic shelf registration (post-effective amendment)
12:00am
F-1
EX-10.5
1i23bri5 npav
4 Oct 18
Registration statement (foreign)
4:48pm
DRS
EX-10.5
0ko2 ayvarjoxi76t
6 Aug 18
Draft registration statement
12:00am
10-K
4yxqijc 878
27 Feb 20
Annual report
4:02pm